Activation of NF-κB in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukaemia: Relation to other prognostic factors

Polish Journal of Pathology

Volumn 62, Issue 1, 2011, Pages 5-11

  Kamieńska, Elzbieta ^a   Ociepa, Tomasz ^a   Wysocki, Mariusz ^b   Kurylak, Andrzej ^b   Matysiak, Michał ^c   Urasiński, Tomasz ^a   Urasińska, Elzbieta ^a   Domagała, Wenancjusz ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Childhood All; NF B; Prognostic factors

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PREDNISONE; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BIOSYNTHESIS; CHILD; DRUG EFFECT; FEMALE; HUMAN; INFANT; MALE; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC AGENTS, HORMONAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; MALE; NF-KAPPA B; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79957956984     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010; 36: 277-285.
2. Szczepański T, Harrison CJ, van Dongen JJ. Genetic aberrations in paediatric acute leukaemias and implications for management of patients. Lancet Oncol 2010; 11: 880-889.
3. Jeha S, Pui CH. Risk-adapted treatment of pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 973-990.
4. Schrappe M. Evolution of BFM trials for childhood ALL. Ann Hematol 2004; 83: 121-123.
5. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappa B activation: from bench to bedside. Exp Biol Med 2008; 233: 21-31.
6. Cilloni D, Martinelli G, Messa F, et al. Nuclear factor-KB as a target for new drug development in myeloid malignancies. Haematologica. 2007; 92: 1224-1229.
7. Hayden MS, Ghosh S. Signaling to NF-kappa B. Genes Dev 2004; 18: 2195-224.
8. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappa B. Cell Death Differ. 2006; 13: 759-772.
9. Gilmore TD. Introduction to NF-kappa B: players, pathways, perspectives. Oncogene. 2006; 25: 6680-6684.
10. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappa B is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
11. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Schei-dereit C. Transcription factor NF-kappa B is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402.
12. Jost PJ, Ruland J. Aberrant NF-kappa B signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007; 109: 2700-2707.
13. Almawi WY, Melemedjian OK. Negative regulation of nuclear factor-kappa B activation and function by glucocorti coids. J Mol Endocrinol 2002; 28: 69-78.
14. Hartmann BL, Geley S, Kofler R. Sequence-specific transcription factors during glucocorticoid-induced apoptosis in acute lymphoblastic leukemia cells. Wien Klin Wochenschr 1999; 111: 360-367.
15. Wuchter C, Krappmann D, Cai Z, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kappa B activity. Leukemia 2001; 15: 921-8.
16. Gu L, Findley HW, Zhou M. MDM2 induces NF- kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p5 3 -independent role of MDM2 in doxoru bicin resistance in acute lymphoblastic leukemia. Blood 2002; 99: 3367-3375.
17. Min DJ, Moskowitz NP, Brownstein C, et al. Diverse path ways mediate chemotherapy-induced cell death in acute lym phoblastic leukemia cell lines. Apoptosis. 2006; 11: 1977-1986.
18. Hafez M, Al-Tonbary Y, El-Bayoumi MA, et al. Markers of apoptosis and proliferation related gene products as predictors of treatment outcome in childhood acute lymphoblastic leukemia. Hematology 2007; 12: 209-218.
19. Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 1605-1621.
20. Deptala A, Bedner E, Gorczyca W, Darzynkiewicz Z. Activation of nuclear factor kappa B (NF-kappaB) assayed by laser scanning cytometry (LSC). Cytometry. 1998; 33: 376-82.
21. Giri DK, Pantazis P, Aggarwal BB. Cellular resistance to vincristine suppresses NF-kappa B activation and apoptosis but enhances c-Jun-NH2-terminal protein kinase activation by tumor necrosis. Apoptosis 1999; 4: 291-301.
22. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 286-290.
23. Scheinman RI, Gualberto A, Jewell CM, et al. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 1995; 15: 943-953.
24. Mukaida N, Morita M, Ishikawa Y, et al. Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem 1994; 269: 13289-13295.
25. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad SciUSA 1994; 91: 752-756.
26. De Bosscher K, Schmitz ML, Vanden Berghe W, et al. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci U S A 1997; 94: 13504-13509.
27. Nissen RM, Yamamoto KR The glucocorticoid receptor inhibits NFkappa B by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000; 14: 2314-2329.
28. Zhang Z, Fuller GM. The competitive binding of STAT3 and NF-kappaB on an overlapping DNA binding site. Biochem Biophys Res Commun 1997; 237: 90-94.